CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Eculizumab

Eculizumab

Last Updated: February 9, 2015

Result type: Reports

Project Number: SF0416-000

Product Line: Reimbursement Review

Generic Name: Eculizumab

Brand Name: Soliris

Manufacturer: Alexion Pharma Canada

Therapeutic Area: Atypical hemolytic uremic syndrome

Indications: Hemolytic Uremic Syndrome, Atypical

Submission Type: Request For Advice

Project Status: Complete

Eculizumab

Files